Finance

Lists
Why is ORX up 5,76%?
Dive Deeper
ORX:STO
Orexo AB
0,90ย SEK
+5,76%
(+0,049) 1D
17 ีถีธีต, 17:29:55 GMT+1  ·   SEK
All symbols
SymbolPriceChange% Change
Generating top insights for ORX...
Open
0,83ย SEK
High
0,98ย SEK
Low
0,83ย SEK
Mkt. cap
315,79ย ีดีฌีถ
Avg. vol.
790,03ย ีฐีฆึ€
Volume
719,07ย ีฐีฆึ€
P/E ratio
0,07
52-wk high
22,55ย SEK
52-wk low
0,80ย SEK
EPS
13,61ย SEK
Shares outstanding
35,13ย ีดีฌีถ
No. of employees
55
Open
0,83ย SEK
High
0,98ย SEK
Low
0,83ย SEK
Mkt. cap
315,79ย ีดีฌีถ
Avg. vol.
790,03ย ีฐีฆึ€
Volume
719,07ย ีฐีฆึ€
P/E ratio
0,07
52-wk high
22,55ย SEK
52-wk low
0,80ย SEK
EPS
13,61ย SEK
Shares outstanding
35,13ย ีดีฌีถ
No. of employees
55
News stories
From web sources and news partners
Barron's
Barron's
·
6 ึ€ีธีบีฅ ีกีผีกีป
Bear Market Watch: What the Charts Say About the S&P 500
Benzinga
Benzinga
·
22 ึ€ีธีบีฅ ีกีผีกีป
Walmart Stock Posts Best 2-Month Run Vs. S&P 500 Since 1975 - Walmart (NASDAQ:WMT)
TradingView
TradingView
·
2 ีชีกีด ีกีผีกีป
Wells Fargo sets 2027 S&P 500 year-end target at 8,200
Traders Union
Traders Union
·
48 ึ€ีธีบีฅ ีกีผีกีป
S&P 500 trades near AVWAP and key retracement lines, Chris Ciovacco notes
Profile
Orexo is a Swedish pharmaceutical company that develops improved pharmaceuticals based on innovative formulation technologies that meet large medical needs. Through presence its in the US market, drugs and digital therapies are commercialized to treat opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with partners. Wikipedia
About Orexo AB
CEONikolaj Sรธrensen
Employees55
Founded1995
Headquarters-
SectorHealth Care
Industry-
Websiteorexo.com
Previous reportsAll values in SEK
Loading Previous Earnings...
Revenue
Net income
All values in SEK
2025 ีฉ. ีคีฅีฏ
2026 ีฉ. ีดึ€ีฟ
2026 ีฉ. ีฐีถีฝ
2026 ีฉ. ีฝีฅีบ
Revenue
3,30ย ีดีฌีถ
5,00ย ีดีฌีถ
3,50ย ีดีฌีถ
800,00ย ีฐีฆึ€
Cost of goods sold
2,60ย ีดีฌีถ
500,00ย ีฐีฆึ€
100,00ย ีฐีฆึ€
100,00ย ีฐีฆึ€
Cost of revenue
2,60ย ีดีฌีถ
500,00ย ีฐีฆึ€
100,00ย ีฐีฆึ€
100,00ย ีฐีฆึ€
Research and development expenses
55,60ย ีดีฌีถ
50,10ย ีดีฌีถ
53,40ย ีดีฌีถ
54,10ย ีดีฌีถ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
28,00ย ีดีฌีถ
37,40ย ีดีฌีถ
58,20ย ีดีฌีถ
15,90ย ีดีฌีถ
Operating expense
80,70ย ีดีฌีถ
80,20ย ีดีฌีถ
106,50ย ีดีฌีถ
62,20ย ีดีฌีถ
Total operating expenses
83,30ย ีดีฌีถ
80,70ย ีดีฌีถ
106,60ย ีดีฌีถ
62,30ย ีดีฌีถ
Operating income
-80,00ย ีดีฌีถ
-75,70ย ีดีฌีถ
-103,10ย ีดีฌีถ
-61,50ย ีดีฌีถ
Other non operating income
-200,00ย ีฐีฆึ€
-100,00ย ีฐีฆึ€
-300,00ย ีฐีฆึ€
100,00ย ีฐีฆึ€
EBT including unusual items
-115,50ย ีดีฌีถ
-104,20ย ีดีฌีถ
-102,30ย ีดีฌีถ
-95,80ย ีดีฌีถ
EBT excluding unusual items
-93,50ย ีดีฌีถ
-104,50ย ีดีฌีถ
-103,00ย ีดีฌีถ
-61,20ย ีดีฌีถ
Income tax expense
100,00ย ีฐีฆึ€
1,00ย ีดีฌีถ
200,00ย ีฐีฆึ€
22,10ย ีดีฌีถ
Effective tax rate
-0,09%
-0,96%
-0,20%
-23,07%
Other operating expenses
-2,90ย ีดีฌีถ
-7,30ย ีดีฌีถ
-5,10ย ีดีฌีถ
-7,80ย ีดีฌีถ
Net income
724,80ย ีดีฌีถ
-133,90ย ีดีฌีถ
-100,40ย ีดีฌีถ
-96,40ย ีดีฌีถ
Net profit margin
21ย 963,64%
-2ย 678,00%
-2ย 868,57%
-12ย 050,00%
Earnings per share
-
-
-2,53
-
Interest and investment income
600,00ย ีฐีฆึ€
4,40ย ีดีฌีถ
2,00ย ีดีฌีถ
1,30ย ีดีฌีถ
Interest expense
-12,20ย ีดีฌีถ
-32,90ย ีดีฌีถ
-
-
Net interest expenses
-11,60ย ีดีฌีถ
-28,50ย ีดีฌีถ
2,00ย ีดีฌีถ
1,30ย ีดีฌีถ
Depreciation and amortization charges
-
-
-
-
EBITDA
-46,80ย ีดีฌีถ
-66,90ย ีดีฌีถ
-94,90ย ีดีฌีถ
-53,40ย ีดีฌีถ
Gain or loss from assets sale
-
-
-
300,00ย ีฐีฆึ€
Upcoming events
AI content may include mistakes. Learn more
Google Apps